Transgene SA (TNG) fair value: what the stock is really worth
As of Sep 28, 2026: fair value of Transgene SA €0.31, price €0.73, upside -58.1%, quality 17 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Transgene SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range €0.5620 – €2.84 · fair‑value band €0.2040 – €0.3825 · the €0.7300 price screens above the €0.3060 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Transgene in your weekly email
Every Wednesday you see whether Transgene is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.
Show more
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastrointestinal adenocarcinoma; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, and BioInvent. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Stock analysis
Transgene SA (TNG) currently trades at €0.7300, while our model-based Fair Value estimate is €0.3060, implying the stock looks roughly 138.5% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: €0.2040 (bear) to €0.3825 (bull), the price of €0.7300 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Transgene SA reported revenue of €137K in FY2025 versus €10.0M in FY2021, a compound −65.8%/yr. Reported net income was −€37.5M in FY2025.
Key figures
Market cap €204M · P/S ratio 28.3 · EPS (TTM) €−0.2600 · Return on equity −54.8% · Return on assets (EBIT) −49.7% · Operating margin −684% · Revenue growth (YoY) −12.2% · Free cash flow −€37.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 51% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −58%, TNG screens richer than that median.
Fair Value models
Bear €0.2040Fair Value €0.3060Bull €0.3825
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 1 year
−97.8%
Revenue growth 28 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.0%
’12
’13
’14
’15
’16
’17
’18
’19
’21
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−804.9% (2020) → −29,978.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 645 stocks
Beats the industry median on 0/7 measures
Overall it trails its industry peers.
Valuation
Quality Score24 · Bottom 25%
Fair Value upside−58.1% · Below median
Profitability
Return on assets−24.2% · Below median
Growth and dividend
Revenue growth−12.2% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.90× · Pricier than median
P/S (TTM)32.12× · Priciest 25%
PEG3.08× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Transgene SA Fair Value". https://www.fairvalue-calculator.com/stock/TNG
Frequently asked questions
Is Transgene SA (TNG) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of €0.3060 versus a price of €0.7300, about −58% upside (overvalued).
What is the fair value of TNG?
Our model-based fair value for Transgene SA is €0.3060 (as of Sep 27, 2026), built from audited fundamentals. The current price: €0.7300.
What is the quality score of TNG?
Transgene SA has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Transgene SA (TNG)?
Our model-based price target is the fair value of €0.3060 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario €0.2040, optimistic scenario €0.3825. It is a calculation from audited fundamentals, not an analyst target.
What is the Transgene SA stock forecast for 2026?
Our models put fair value at €0.3060, about −58% upside versus a price of €0.7300 (overvalued). Cautious scenario €0.2040, optimistic scenario €0.3825. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Transgene SA (TNG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Transgene SA it is €0.3060 per share (as of Sep 27, 2026), against a price of €0.7300. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Transgene SA stock overvalued or undervalued in 2026?
As of Sep 27, 2026, TNG trades above its calculated fair value: price €0.7300, fair value €0.3060, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TNG?
No. The price is what the market pays today (€0.7300); the fair value is what the company's own numbers justify (€0.3060). For Transgene SA the two are €0.4240 per share apart. That gap is exactly why we show both numbers side by side.
How much is Transgene SA worth?
The market values Transgene SA at about €204M (market capitalisation, as of Sep 27, 2026). Per share that is €0.7300; our models calculate a fair value of €0.3060 per share.
What do the bullish and bearish scenarios say about TNG?
Our models span a range for Transgene SA: cautious scenario €0.2040, base €0.3060, optimistic €0.3825 per share (as of Sep 27, 2026, price €0.7300). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of TNG?
The PEG ratio of Transgene SA is 3.08 (P/E divided by earnings growth, as of Sep 27, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Transgene SA (TNG)?
Balance-sheet figures for Transgene SA (as of Sep 27, 2026): return on equity −54.8%. They feed the Quality Score of 17/100, which measures business quality independently of the share price.
How far is TNG from its 52-week high?
Transgene SA trades at €0.7300, about 51% below its 52-week high of €1.48 and 3% above the low of €0.7060 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of €0.3060 is for.
Which stocks are comparable to Transgene SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Transgene SA stock attractive at the current price?
The data as of Sep 27, 2026: price €0.7300, calculated fair value €0.3060 (−58%), Quality Score 17/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TNG calculated?
We run Transgene SA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €0.3060, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.9 % above its aggregate fair value. Transgene SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Transgene SA (TNG)?
The closing price on Sep 28, 2026 was €0.7300. Our model-based fair value is €0.3060, about −58% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Transgene SA right now?
The price sits above even our optimistic bull case (€0.3825). The favourable scenario is already priced in. Weak quality (17/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€0.2040 to €0.3825) leaves room in how you read the outcome.
Key figures of Transgene SA
How large is the market capitalisation of Transgene SA (TNG)?
The market capitalisation of Transgene SA is €204M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Transgene SA (TNG)?
The price-to-sales ratio of Transgene SA is 28.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Transgene SA (TNG)?
Earnings per share at Transgene SA are €−0.2600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Transgene SA (TNG)?
The return on equity (ROE) of Transgene SA is −54.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Transgene SA (TNG)?
On an EBIT basis the return on assets of Transgene SA is −49.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Transgene SA (TNG)?
The operating margin of Transgene SA is −684% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Transgene SA (TNG)?
Revenue at Transgene SA is growing −12.2% versus a year earlier (3y avg −64.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Transgene SA (TNG) generate?
The free cash flow of Transgene SA is −€37.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Transgene SA (TNG) hold?
Transgene SA holds more cash than debt, €4.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Transgene SA in the live analysis
One click puts Transgene SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
